$184,786,391

Procurement of therapeutics to treat Ebola, Sudan, and Marburg virus infections as part of U.S. epidemic preparedness.

Ensures domestic supply of critical antivirals for high-mortality viral hemorrhagic fevers; strengthens pandemic readiness against emerging infectious disease threats.

Signals sustained demand for specialized biopharmaceutical manufacturing capacity; may incentivize domestic production scale-up for rare but critical therapeutics.

Reduces U.S. dependence on foreign pharmaceutical supply chains for pandemic-critical drugs; supports domestic biotech resilience against future outbreaks.